Kyverna Therapeutics

(NASDAQ) KYTX

Current Price$9.48

Market Cap$576.95M

Since IPO (2024)-68%

5 YearN/A

1 Year+335%

1 Month+1%

Kyverna Therapeutics Financials at a Glance

Market Cap

$576.95M

Revenue (TTM)

$0.00

Net Income (TTM)

$156.40M

EPS (TTM)

$-3.28

P/E Ratio

-2.89

Dividend

$0.00

Beta (Volatility)

1.96 (High)

Dividend

$0.00

Beta (Volatility)

1.96 (High)

Price

$9.48

Volume

1,195,416.867

Open

$10.72

Price

$9.48

Volume

1,195,416.867

Open

$10.72

Previous Close

$9.49

Daily Range

$9.31 - $10.72

52-Week Range

$2.06 - $13.67

Dividend

$0.00

Beta (Volatility)

1.96 (High)

Price

$9.48

Volume

1,195,416.867

Open

$10.72

Previous Close

$9.49

Daily Range

$9.31 - $10.72

52-Week Range

$2.06 - $13.67

KYTX News

Everyone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?

Alex CarchidiFeb 25, 2024

KYTX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kyverna Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

130

CEO

Warner Biddle

Website

www.kyvernatx.com

Headquarters

Emeryville, CA 94608, US

KYTX Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-75%

Return on Capital

-72%

Return on Assets

-61%

Earnings Yield

-34.60%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$576.95M

Shares Outstanding

60.80M

Volume

1.20M

Avg. Volume

873.66K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$169.83M

EBITDA

$159.02M

Operating Cash Flow

$153.71M

Capital Expenditure

$5.00K

Free Cash Flow

$153.72M

Cash & ST Invst.

$279.25M

Total Debt

$29.03M

Kyverna Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$351.00K

+29.9%

Gross Margin

0.00%

N/A

Market Cap

$576.95M

N/A

Market Cap/Employee

$5.15M

N/A

Employees

112

N/A

Net Income

$39.73M

+11.0%

EBITDA

$41.02M

+7.0%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$227.50M

-3.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$6.96M

+107.5%

Short Term Debt

$1.99M

-44.6%

Return on Assets

-60.85%

N/A

Return on Invested Capital

-72.04%

N/A

Free Cash Flow

$41.60M

+7.4%

Operating Cash Flow

$41.60M

+7.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CTNMContineum Therapeutics, Inc. Class A Common Stock

CTNMContineum Therapeutics, Inc. Class A Common Stock$13.72-3.45%

ALLOAllogene Therapeutics, Inc.

ALLOAllogene Therapeutics, Inc.$2.00-6.54%

LYELLyell Immunopharma, Inc.

LYELLyell Immunopharma, Inc.$17.92-5.78%

LXEOLexeo Therapeutics, Inc. Common Stock

LXEOLexeo Therapeutics, Inc. Common Stock$5.09-7.45%

AVIRAtea Pharmaceuticals, Inc.

AVIRAtea Pharmaceuticals, Inc.$4.10-3.98%

CABACabaletta Bio, Inc.

CABACabaletta Bio, Inc.$3.31-8.31%

SLNSilence Therapeutics plc

SLNSilence Therapeutics plc$6.10-14.45%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ONDSOndas

ONDSOndas$10.62-0.05%

FFord Motor Company

FFord Motor Company$13.40-0.07%

POETPoet Technologies

POETPoet Technologies$15.97-0.22%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$15.06-0.10%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$75.34-0.05%

FIGFigma

FIGFigma$22.92+0.13%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$42.98+0.05%

Questions About KYTX

What is the current price of Kyverna Therapeutics?

Kyverna Therapeutics is trading at $9.49 per share.

What is the 52-week range for Kyverna Therapeutics?

Over the past 52 weeks, Kyverna Therapeutics has traded between $2.06 and $13.67.

How much debt does Kyverna Therapeutics have?

As of the most recent reporting period, Kyverna Therapeutics reported total debt of $33.76M.

How much cash does Kyverna Therapeutics have on hand?

Kyverna Therapeutics reported $32.19M in cash and cash equivalents in its most recent financial results.

What is Kyverna Therapeutics’s dividend yield?

Kyverna Therapeutics does not currently have a dividend yield.

Kyverna Therapeutics

Kyverna Therapeutics Financials at a Glance

KYTX News

Everyone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?

KYTX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Kyverna Therapeutics

KYTX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Kyverna Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About KYTX

What is the current price of Kyverna Therapeutics?

What is the 52-week range for Kyverna Therapeutics?

How much debt does Kyverna Therapeutics have?

How much cash does Kyverna Therapeutics have on hand?

What is Kyverna Therapeutics’s dividend yield?

Premium Investing Services